Investing.com -- CRISPR Therapeutics AG (NASDAQ:CRSP)股价周二下跌6.75%,此前该公司宣布拟发行3.5亿美元可转换优先债券。 这家基因编辑公司表示,计划根据《证券法》第144A条规则,向合格机构买家私募发行2031年到期的可转换优先债券。该公司还预计将授予初始购买者一项选择权,可额外购买最多5,250万美元本金总额的债券。 这些债券将是该公司的 ...

Current shareholders were thrown an unexpected curveball that they actually should have been expecting.

CRISPR Therapeutics (NasdaqGM:CRSP) has announced a $350 million offering of convertible senior notes. The securities are a form of debt that may convert into equity under certain conditions. The ...

CRISPR Therapeutics AG (NASDAQ:CRSP) is one of the 10 most shorted biotech stocks to buy according to hedge funds. On ...

Now, it’s worth noting Stock Advisor’s total average return is 892 % — a market-crushing outperformance compared to 194% for ...

CRISPR isn't profitable, but it does have an approved gene therapy treatment with loads of potential.

CRISPR Therapeutics AG (NASDAQ:CRSP) shares declined 6.75% on Tuesday after the company revealed plans to raise $350 million through a convertible senior notes offering. The gene-editing firm said it ...

The gene-editing company said it intends to offer the convertible senior notes due 2031 in a private offering to qualified institutional buyers pursuant to Rule 144A under the Securities Act. The ...

CRISPR Therapeutics reached a significant milestone a couple of years ago: its first product approval. The company’s stock, once a highflier, has declined from its peak. CRISPR Therapeutics (NASDAQ: ...

CRISPR Therapeutics AG CRSP shares moved lower Tuesday after the biotechnology company outlined plans to raise capital through a new convertible debt offering. The gene-editing firm said it intends to ...